Cost/Benefit of Hepatitis C Treatment: It Does Not End with SVR
- PMID: 29550966
- PMCID: PMC5955839
- DOI: 10.1007/s10620-018-5014-7
Cost/Benefit of Hepatitis C Treatment: It Does Not End with SVR
Comment on
-
Hypervigilance to a Gluten-Free Diet and Decreased Quality of Life in Teenagers and Adults with Celiac Disease.Dig Dis Sci. 2018 Jun;63(6):1438-1448. doi: 10.1007/s10620-018-4936-4. Epub 2018 Jan 31. Dig Dis Sci. 2018. PMID: 29387990
References
-
- Younossi ZM, Park H, Saab S, Ahmed A, Dieterich D, Gordon SC. Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther. 2015;41:544–563. - PubMed
-
- Younossi ZM, Singer ME, Mir HM, Henry L, Hunt S. Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients. J Hepatol. 2014;60:530–537. - PubMed
-
- Chhatwal J, He T, Hur C, Lopez-Olivo MA. Direct-Acting Antiviral Agents for Patients With Hepatitis C Virus Genotype 1 Infection Are Cost-Saving. Clin Gastroenterol Hepatol. 2017;15:827–837 e828. - PubMed
-
- Petta S, Cabibbo G, Enea M, Macaluso FS, Plaia A, Bruno R, Gasbarrini A, et al. Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. Dig Liver Dis. 2014;46:936–942. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
